SAR443765 / LUNSEKIMIG
LTS18300
Phase 2 small_molecule active
Quick answer
SAR443765 / LUNSEKIMIG for Chronic rhinosinusitis with nasal polyps is a Phase 2 program (small_molecule) at Sanofi Pharma Bristol-Myers Squibb with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Sanofi Pharma Bristol-Myers Squibb
- Indication
- Chronic rhinosinusitis with nasal polyps
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active